FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,816,481 | -90.2% | 2,271,925 | -78.0% | 0.00% | -100.0% |
| Q2 2023 | $49,094,216 | -41.9% | 10,313,911 | -30.5% | 0.00% | -40.0% |
| Q1 2023 | $84,531,479 | -29.4% | 14,830,084 | +24.9% | 0.01% | +25.0% |
| Q4 2022 | $119,777,562 | +22.0% | 11,870,918 | +170.9% | 0.00% | -33.3% |
| Q3 2022 | $98,215,000 | -24.8% | 4,382,634 | -16.8% | 0.01% | -25.0% |
| Q2 2022 | $130,594,000 | -3.0% | 5,270,135 | +51.8% | 0.01% | +14.3% |
| Q1 2022 | $134,626,000 | -15.4% | 3,472,432 | +27.7% | 0.01% | -12.5% |
| Q4 2021 | $159,077,000 | +12.7% | 2,718,793 | +14.2% | 0.01% | +14.3% |
| Q3 2021 | $141,154,000 | -20.8% | 2,381,539 | +15.9% | 0.01% | -22.2% |
| Q2 2021 | $178,314,000 | +9.1% | 2,054,546 | +3.6% | 0.01% | 0.0% |
| Q1 2021 | $163,515,000 | -14.7% | 1,983,196 | -5.9% | 0.01% | -25.0% |
| Q4 2020 | $191,623,000 | +65.2% | 2,107,373 | -27.4% | 0.01% | +50.0% |
| Q3 2020 | $115,997,000 | +9.0% | 2,902,108 | -6.4% | 0.01% | 0.0% |
| Q2 2020 | $106,417,000 | +94.3% | 3,101,641 | +25.8% | 0.01% | +60.0% |
| Q1 2020 | $54,760,000 | +17.4% | 2,465,539 | +3.4% | 0.01% | +66.7% |
| Q4 2019 | $46,657,000 | +10.8% | 2,384,132 | -12.0% | 0.00% | 0.0% |
| Q3 2019 | $42,098,000 | -14.6% | 2,710,736 | +11.6% | 0.00% | -25.0% |
| Q2 2019 | $49,289,000 | +8.1% | 2,428,026 | -6.5% | 0.00% | 0.0% |
| Q1 2019 | $45,615,000 | +74.8% | 2,596,179 | +27.7% | 0.00% | +100.0% |
| Q4 2018 | $26,091,000 | -18.1% | 2,033,588 | +4.0% | 0.00% | 0.0% |
| Q3 2018 | $31,843,000 | +40.8% | 1,954,840 | -2.0% | 0.00% | 0.0% |
| Q2 2018 | $22,615,000 | +194.3% | 1,993,912 | +153.3% | 0.00% | +100.0% |
| Q1 2018 | $7,685,000 | +135.2% | 787,163 | +47.1% | 0.00% | – |
| Q4 2017 | $3,267,000 | +81.9% | 534,969 | +17.9% | 0.00% | – |
| Q3 2017 | $1,796,000 | +25.0% | 453,661 | +2.3% | 0.00% | – |
| Q2 2017 | $1,437,000 | – | 443,462 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |